William Blair Weighs in on CVRx's Q2 Earnings (NASDAQ:CVRX)

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Equities researchers at William Blair dropped their Q2 2025 earnings per share estimates for CVRx in a report released on Wednesday, February 5th. William Blair analyst M. Andrew now forecasts that the company will post earnings per share of ($0.54) for the quarter, down from their prior estimate of ($0.50). William Blair has a "Outperform" rating on the stock. The consensus estimate for CVRx's current full-year earnings is ($1.89) per share. William Blair also issued estimates for CVRx's Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($2.06) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.92) EPS.

CVRX has been the subject of several other reports. Lake Street Capital boosted their target price on CVRx from $12.00 to $15.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Craig Hallum boosted their price objective on CVRx from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, January 17th. Canaccord Genuity Group raised their target price on shares of CVRx from $22.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, February 5th. Piper Sandler upped their price target on shares of CVRx from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $14.00 price objective on shares of CVRx in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $17.83.

CVRx Stock Down 2.1 %

Shares of NASDAQ CVRX traded down $0.32 during mid-day trading on Friday, reaching $14.57. The company had a trading volume of 106,926 shares, compared to its average volume of 264,757. The firm has a 50 day simple moving average of $14.66 and a two-hundred day simple moving average of $11.89. CVRx has a 52-week low of $6.40 and a 52-week high of $24.55. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76. The stock has a market cap of $353.47 million, a P/E ratio of -5.42 and a beta of 1.30.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 96.36%.

Hedge Funds Weigh In On CVRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in CVRX. Bank of New York Mellon Corp boosted its stake in shares of CVRx by 4.5% in the fourth quarter. Bank of New York Mellon Corp now owns 30,377 shares of the company's stock valued at $385,000 after buying an additional 1,296 shares in the last quarter. Jane Street Group LLC boosted its position in shares of CVRx by 36.1% during the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company's stock worth $168,000 after purchasing an additional 5,053 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of CVRx by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company's stock worth $2,600,000 after purchasing an additional 6,443 shares during the period. Calamos Advisors LLC purchased a new position in shares of CVRx in the 4th quarter valued at about $134,000. Finally, SG Americas Securities LLC acquired a new stake in shares of CVRx in the third quarter valued at about $108,000. Institutional investors and hedge funds own 75.27% of the company's stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.